Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

The triple-negative subtype: new ideas for the poorest prognosis breast cancer.

Curigliano G, Goldhirsch A.

J Natl Cancer Inst Monogr. 2011;2011(43):108-10. doi: 10.1093/jncimonographs/lgr038.

PMID:
22043054
2.

Novel treatment approaches for triple-negative breast cancer.

Telli ML, Ford JM.

Clin Breast Cancer. 2010;10 Suppl 1:E16-22. doi: 10.3816/CBC.2010.s.003. Review.

PMID:
20587403
3.

Characteristics of triple-negative breast cancer.

de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC.

J Cancer Res Clin Oncol. 2011 Feb;137(2):183-92. doi: 10.1007/s00432-010-0957-x. Epub 2010 Nov 11. Review.

4.

Dissecting the heterogeneity of triple-negative breast cancer.

Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M.

J Clin Oncol. 2012 May 20;30(15):1879-87. doi: 10.1200/JCO.2011.38.2010. Epub 2012 Mar 26. Review.

PMID:
22454417
5.

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE.

J Clin Oncol. 2010 Mar 1;28(7):1145-53. doi: 10.1200/JCO.2009.22.4725. Epub 2010 Jan 25.

6.

Triple-negative breast cancer.

Bartsch R, Ziebermayr R, Zielinski CC, Steger GG.

Wien Med Wochenschr. 2010 Apr;160(7-8):174-81. doi: 10.1007/s10354-010-0773-6. Review.

PMID:
20473728
7.

Triple-negative breast cancer: disease entity or title of convenience?

Carey L, Winer E, Viale G, Cameron D, Gianni L.

Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. doi: 10.1038/nrclinonc.2010.154. Epub 2010 Sep 28. Review.

PMID:
20877296
8.

Therapeutic options for triple-negative breast cancers with defective homologous recombination.

Jaspers JE, Rottenberg S, Jonkers J.

Biochim Biophys Acta. 2009 Dec;1796(2):266-80. doi: 10.1016/j.bbcan.2009.07.001. Epub 2009 Jul 17. Review.

PMID:
19616605
9.

Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?

Berrada N, Delaloge S, André F.

Ann Oncol. 2010 Oct;21 Suppl 7:vii30-5. doi: 10.1093/annonc/mdq279. Review.

PMID:
20943632
10.

[Novel target therapies used in breast cancer management].

Semiglazova TIu, Semiglazov VV, Filatova LV, Gershanovich ML, Chudenko VA, Latipova DKh, Luk'ianchikova VS, Dashian GA, Paltuev RM.

Vopr Onkol. 2011;57(5):592-600. Review. Russian. No abstract available.

PMID:
22238928
11.

Management of triple negative breast cancer.

Oakman C, Viale G, Di Leo A.

Breast. 2010 Oct;19(5):312-21. doi: 10.1016/j.breast.2010.03.026. Epub 2010 Apr 10. Review.

PMID:
20382530
12.

Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.

Shibata H, Miuma S, Saldivar JC, Huebner K.

Cancer Sci. 2011 Oct;102(10):1882-8. doi: 10.1111/j.1349-7006.2011.02016.x. Epub 2011 Jul 21.

13.

Past, present, and future challenges in breast cancer treatment.

Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC.

J Clin Oncol. 2014 Jul 1;32(19):1979-86. doi: 10.1200/JCO.2014.55.4139. Epub 2014 Jun 2. No abstract available.

14.

"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.

Nanda R.

Semin Oncol. 2011 Apr;38(2):254-62. doi: 10.1053/j.seminoncol.2011.01.007. Review.

PMID:
21421115
15.

Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.

16.

Treatment options for patients with triple-negative breast cancer.

Santana-Davila R, Perez EA.

J Hematol Oncol. 2010 Oct 27;3:42. doi: 10.1186/1756-8722-3-42. Review.

17.

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A.

Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.

PMID:
21862407
18.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.

Clin Cancer Res. 2007 Apr 15;13(8):2329-34.

19.

Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES.

Cancer. 2013 May 15;119(10):1776-83. doi: 10.1002/cncr.27995. Epub 2013 Feb 21.

20.

Triple-negative breast cancer: current state of the art.

Rastelli F, Biancanelli S, Falzetta A, Martignetti A, Casi C, Bascioni R, Giustini L, Crispino S.

Tumori. 2010 Nov-Dec;96(6):875-88. Review.

Supplemental Content

Support Center